biote Corp. Class A (BTMD)

Biote Corp.'s stock price has been impacted by several events over the past six months, hitting a 52-week low of $2.03 and a 52-week high of $5.00 within the last year. As of early February 2026, the stock has experienced a significant decline, with a -51.8% return over the past six months and a -62.2% return over the past year. In Q3 2025, Biote reported earnings per share (EPS) of $0.22, exceeding analysts' expectations, leading to a stock increase. Preliminary results for Q4 2025 indicated that revenue and EBITDA expectations were falling short of prior estimates. Strategic initiatives and operational disruptions have impacted new clinic additions, procedure volumes, and clinic attrition. A product recall in January 2026 is expected to result in a $1.3 million charge for Q4 2025, with additional recall costs estimated at $1.0 million in 2026. Analysts have a consensus "Hold" rating for Biote, with a predicted upside of 154.11% based on 12-month forecasts from some analysts.

Information regarding specific demand seasonality for Biote Corp.'s products and services is not explicitly detailed in the available search results. A definitive statement on the demand seasonality for Biote's products and services cannot be provided without further access to proprietary information.

Biote Corp. is a woman-led biopharmaceutical company in the hormone optimization and therapeutic wellness sector, founded in 2012 and headquartered in Irving, Texas. It focuses on personalized hormone therapy, providing the "Biote Method" platform to healthcare practitioners, including medical education, software, and marketing support. Biote also produces dietary supplements and sterile pellet insertion kits, and has recently added GLP-1s to its portfolio, though it currently represents an immaterial amount of revenue.

Biote Corp. has a significant market presence with over 2,500 healthcare providers across the United States and an expanding international footprint. The company's headquarters are located in Irving, Texas.

Biote Corp. operates in the growing hormone optimization and therapeutic wellness sector, focusing on science-based approaches. However, its brand reputation has faced challenges, with analysts generally rating Biote lower than other "medical" companies. A product recall in January 2026 and operational disruptions have negatively impacted consumer trust and the company's operational efficiency.

Biote Corp. has a diverse ownership structure, with institutional investors holding a significant portion of the company's shares. Institutions hold approximately 41.95% of the shares, hedge funds hold 21.17%, the general public holds 24.34%, and individual insiders hold 12.54%. Major institutional shareholders include 325 Capital Llc, Bandera Partners LLC, BlackRock, Inc., Vanguard Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Acadian Asset Management Llc, Geode Capital Management, Llc, Dimensional Fund Advisors Lp, and State Street Corp.